In this study, methotrexate (MTX) was compared with placebo in the treatment of systemic sclerosis (scleroderma, SSc) in a 24 week randomized double-blind trial, followed by an observational trial of 24 weeks duration. Twenty-nine scleroderma patients were allocated to receive weekly injections of either 15 mg MTX or placebo. Patients who responded favourably after 24 weeks continued with the same regimen for a further 24 weeks; those who showed a poor response on placebo were allocated to further treatment with 15 mg MTX weekly, and those who responded poorly to treatment with 15 mg MTX weekly had their doses increased to 25 mg. A favourable response was defined as an improvement of total skin score (TSS) by ^30% , of single breath diffusion capacity (DLco) by ^ 15%, or of the score on a visual analogue scale of general well-being (VAS) by ^30% , provided that such improvements were not accompanied by persistent digital ulcerations or worsening of DLco ^ 15%. Seventeen patients were allocated to MTX treatment and 12 to treatment with placebo. After 24 weeks, a significantly larger number of patients receiving MTX (n = 8, 53%) who completed the first 24 weeks of the study had responded favourably compared to patients receiving placebo (n = 1, 10%, P = 0.03). Comparison of separate variables between the two treatment groups by intention-to-treat analysis at week 24 showed improvement in the MTX group of TSS (P = 0.06) and creatinine clearance (P = 0.07). At week 48, 13 patients received MTX from the start of the study and nine during 24 weeks. From these 22 patients, 15 (68%) responded favourably and compared with the start of the study they showed significant improvement of TSS (P = 0.04), VAS (P = 0.02), grip strength of the right hand (P = 0.02) and ESR (P = 0.01). Although the number of patients enrolled in this study is small, these results suggest that in a group of patients with active systemic sclerosis, low-dose MTX seems to be more effective than placebo according to pre-defined response criteria. K ey w o r d s : Systemic sclerosis, Methotrexate, Double-blind placebo-controlled treatment, Side-effects. System ic sclerosis (SSc) or scleroderma is a multisystemic disease characterized by excessive deposition of collagen and other extracellular matrix components by fibroblasts, damage to the endothelium o f small vessels, resulting in intimai hyperplasia and tissue ischaemia, and activation of the immune system. These phenomena may lead to progressive fibrosis of the skin, muscles, joints and internal organs, accounting for many of the clinical manifestations [1,2]. The natural course o f the disease may vary: a few patients experience spontaneous remission; the majority under go progression o f skin and internal organ involvement, resulting in considerable morbidity and ultimately in death. Several studies have given estimates o f 5 yr cumulative survival rates ranging from 34 to 73% [3]. Involvement of heart, lung or kidney, the presence of antitopoisomerase-I autoantibodies and diffuse skin involvement adversely affect outcome [4-6]. SSc is a rare disease, with an estimated annual incidence rate o f
new cases per million
. Its pathogenesis is unclear, but evidence suggests an autoimmune or vascular aetiology [8] . N o treatment has proven convincingly to be effective. Several studies have reported favourable effects of certain drugs, but most o f them consist of case reports, uncontrolled trials or studies with historical controls [9] [10] [11] [12] [13] [14] [15] . Placebo-controlled, double-blind trials in SSc are scarce, and have given negative or inconclusive results [16] [17] [18] [19] [20] [21] [22] .
Methotrexate (MTX) is an antifolate drug. In low dosages it has shown favourable effects in the treatment of autoimmune diseases such as rheumatoid arthritis (RA) [23] [24] [25] [26] [27] and dermato-and polymyositis [28, 29] . We recently reported the results o f a 1 yr pilot study in SSc patients treated with low-dose MTX. In the majority of the patients, cutaneous symptoms im proved within 6 months and no further internal organ deterioration was detected [30] . Similar encouraging observations have been reported in the meantime [31, 32] . To obtain more data about the role of MTX in the treatment of SSc, we conducted a double-blind trial comparing MTX and placebo, focusing on the efficacy and toxicity of these treatments, and on the differences between responders and non-responders on MTX treatment.
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PATIENTS A N D METHODS
The inclusion criteria for the trial consisted of the preliminary criteria for the classification of SSc of the American Rheumatism Association [33] and the requirement that disease duration from the first signs of skin thickening was < 3 yr. Patients with longer disease duration were also included if they had experienced a progression o f skin thickening, persistent digital ulcerations, or a deterioration in pulmonary function, during the last 6 months. All patients voluntarily signed an informed consent form; the study protocol was approved by the institution's ethical committee.
We applied the following exclusion criteria; age < 16yr; the presence of another connective tissue disease or SSc-like illness related to exposure or ingestion; the presence of acute or chronic infection; pregnancy or childbearing potential without an acceptable means o f contraception; the presence of liver disease, defined as a value exceeding twice the upper limit o f normal for a hepatic function test or the presence of a known liver disease; serum creatinine level >130jUmol/l or a creatinine clearance rate 50 ml/min as estimated by the method o f Cockcroft and Gault [34] ; total lung capacity (TLC), vital lung capacity (VC) or single breath diffusion capacity for carbon monoxide (DLCo) < 50% of its predicted value; a leucocyte count o f < 3 .5 x 109/1 or a platelet count <150 X I09/1; the presence of a concurrent neoplastic disease; the presence of insulin-dependent diabetes mellitus; alcohol abuse (> 4 o z/d a y ); the use o f an antifolate drug other than MTX, such as suiphonamide derivates, allopurinol or probenecid; and the presence of active peptic ulcer disease.
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multicentre trial. The study protocol was reviewed and approved by institutional viewboards at each participating clinical centre. Patients were randomly allocated to treatment with either MTX (Ledertrexate, Nederland bv, The Netherlands) or placebo, both of which were administered weekly by i.m. injection. The two groups were balanced for disease duration (time between onset o f skin thickening and entry to the trial) and extent o f skin involvement, known factors for SSc. The weekly dose of MTX was initially 15 mg. Potentially disease-modifying drugs, such as D-penicillamine and colchicine, were discontinued at least 3 months prior to study entry.
Since there is no consensus concerning the outcome measures to be used in assessing disease activity and, hence, response to treatment in SSc, we set up our own criteria by which response can be evaluated. We based them arbitrarily on data from previous studies and on our own experience. They employ the following variables: total skin score (TSS), which is the sum of scores o f 0 -4 obtained manually at 26 anatomic locations, described by Steen et al. [ 24 weeks of the trial. The clinical examiner and the patients were blind regarding the changes in treatment; the treatment code was broken only after all patients had completed the 48 week study. All subjects were out-patients at the time of enrolment and were admitted to hospital during the course of the study only in the event that severe complications occurred.
Clinical assessment
At study entry, a detailed medical history was taken and the patient was given a thorough physical examination. Each patient was evaluated monthly during the trial year by the same investigator 
Concurrent medication
Concurrent treatment with corticosteroids at dosages not exceeding 10 mg/day, non-steroidal anti inflammatory drugs, analgesics, nifedipene, ketanserine, cimetidine or omeprazole were permitted. No changes in dosages were permitted from at least 8 weeks before study entry until the end of the trial.
was
Adverse reactions and withdrawals from the study
At each visit, patients were routinely questioned about symptoms related to MTX toxicity. The trial medication was temporarily withheld if the WBC count < 3 .0 X 10l,/l, if the platelet count was < 150 X 107U if liver enzyme levels exceeded three times the upper limit of normal or if serum creatinine exceeded 160/jm ol/l, for two consecutive measurements. Treatment was resumed once the values had normalized. If the same abnormality reoccurred a second time, after recovery the patients received a dose reduced by 50%. A third occurrence resulted in the patient being permanently withdrawn from the study. Patients who failed to keep scheduled appointments at the clinic or whose clinical conditions deteriorated to such an extent as to necessitate other therapy were also permanently withdrawn.
Statistical analysis *
Categorical variables were compared with Fisher's
Wilcoxon MTX with those in the placebo group. Differences were calculated by intention-to-treat analysis (i.e. all patients were analysed in the group to which they were assigned) and by same drug treatment analysis. Ninety-five per cent confidence intervals were lated. For changes within the MTX group, the sign rank test was used. P values of 0.05 or less were considered significant.
RESULTS
Patient ch or act er ist i cs
Fifty-seven patients were referred to participate in this trial. Twenty-eight of these patients either did not fulfil the inclusion criteria or were not included because of the exclusion criteria, thus leaving 29 patients who were enrolled in the study. Seventeen were allocated to MTX treatment and 12 to placebo treatment, difference in numbers resulted from the fact that by mistake two patients in the MTX group were initially recorded as belonging to the placebo group. The error was discovered after breaking the code at the end of the study. Owing to this error, the number of patients with diffuse and limited cutaneous involvement is also different, although not statistically significant, in both groups. Tables I and II give the initial demographic, clinical and laboratory data of the two groups. The (Table II) . There were no significant re n ces between the two groups with regard to internal organ involvement or previous treatment.
Response to treatment
Eight (53%) o f the 15 patients in the MTX group who had completed the first 24 weeks had responded favour ably after 24 weeks, whereas nine (90%) of the patients receiving placebo and completing the first 24 weeks did not res favourably (Fig. 1) . is 0.03). The power lor o f responders was 0.67. measurements l or the mean difference in those numeric variables that were part o f the response criterion were <0.30 in each variable measured. The favourable response among the patients receiving MTX was due to improvement in TSS in three cases, to improvement in VAS in four and to improvement in both in one case. One patient whose VAS improved ^ 30% was classified as a non-responder, owing to a 5*15% decrease in DLco. The patient who responded while undergoing placebo treatment had a ^30% reduction in TSS.
During the first 24 weeks of treatment, two patients in each treatment group had to be withdrawn from Table III 
Comparison of variables between groups after 24 weeks The differences between the initial and week 24 values of the clinical and laboratory variables ai shown in
Comparison of variables after 48 weeks of methotrexate treatment
The week 48 values were compared with the initial values of the patients treated with MTX throughout the trial. Improvements were found in VAS (P and grip of the right hand (P 1 .1 ( -3 .4 , 1. 3) -0 . 5 ( -2 .2 , 1.2) -2 .7 ( -6 .7 , 1.4)  -1 .7 ( -4 .9 , 1.6 Table V . The difference between the two groups regarding disease duration was due to the presence of two patients with longstanding disease among the responders, but was not significant. Significantly more women than men favourably (P -0.05). Antitopoisomerase-I antibodies seemed to be identified more frequently non-responders (P between 0.06). *e were non-r with respect to any of the other variables that were tested at study
TABLE III Clinical and laboratory variables: differences after 24 weeks of treatment between methotrexate-and placebo-treated groups, by intention-to
VC (% predicted
Responders versus non-responders Of the 15 patients who could be classified as responders at the end o f the trial, eight achieved a ^5 30% improvement in TSS, six a ^ 30% improvement in VAS and one a ^30% improvement in both. The initial values and the differences between the week 48 values and the initial values o f clinical and laboratory
Diffuse and limited skin involvement, short and long disease duration
There were no significant differences changes that occurred among patients with diffuse skin involvement and those that occurred among patients with limited skin involvement, or between the changes that occurred among patients with disease duration of > 1 yr and those that occurred among patients with disease duration of < 1 yr (data not shown).
Withdrawals and adverse reactions
Withdrawals and adverse reactions are summarized in Table VI findings o f our pilot study [30] , in which skin thickening was reversed within 6 months of the beginning of MTX therapy, and no further internal organ deterioration occurred. It was therefore felt that, because of the seriousness o f SSc, a potentially beneficial treatment could not be withheld from patients in a placebo group for more than 6 months. Therefore an evaluation was made after 24 weeks, using response criteria that were defined prior to the start of the study. On the basis o f this evaluation, patients remained either on the same drug regimen, changed from placebo to 15 mg MTX per week or had the MTX dosage increased from 15 to 25 mg weekly. Although these changes in therapy were blinded to the clinical investigator, it appeared at the end of the study, when the treatment code was broken, that only one patient had responded to placebo. Because o f this fact, the initial set-up of this study as a 48-week double-blind placebo-controlled trial could not be fulfilled; the placebo-controlled double-blind part o f this study therefore lasted 24 weeks, making the period between week 24 and 48 an observational study. The rarity of SSc limits the number of patients available for trials, unless multicentre trials with multiobserver examinations are undertaken. However, multiobserver examinations are liable to diminish the reliability of TSS, which is the most important marker of disease progress. We chose one observer in this multicentre trial as TSS is at least as reliable in SSc as joint count is in rheumatoid arthritis, provided that it is evaluated serially by a single investigator [35] .
The Although the number o f patients included in this study was small, we found that significantly more patients responded favourably to MTX treatment than placebo after 24 weeks. Analysis of results at week 48 between the two groups could not be carried out since at week 24 all placebo-treated patients, except one, were switched to MTX treatment according to the study protocol. Analysis of MTX-treated patients at week 48, who completed the study, showed that 68% of the patients in the present study benefited from MTX treatment.
Low-dose MTX is suspected of impairing renal function, principally glomerular and tubular function, especially when it is used in combination with other nephrotoxic drugs [37, 38] . We found no reduction in renal function, as measured by creatinine clearance rate, as we observed in the pilot study. This may have been because only a few patients in the present study used potentially nephrotoxic drugs (non-steroidal anti-inflammatory drugs or cimetidine at a constant dose).
Only one patient had to be permanently withdrawn from the study because of side-effects (severe headache) attributable to MTX. MTX would therefore appear to be reasonably well tolerated and safe in low, weekly, i.m. dosages. The number of adverse reactions was relatively high, but in general minor and manageable.
The occurrence of transient hepatic function disturb ances in six patients and pancytopenia in one emphasizes the necessity of closely monitoring hepatic function tests and blood cell counts.
More patients whose serum was bodies is also known to be associated with an unfavourable prognosis in SSc. The dosage of 15 mg MTX weekly seemed to be sufficient for the majority of patients who responded favourably. A higher dose of 25 mg may be necessary in those cases in which it is not.
In spite of the small number of patients enrolled in this study, we could demonstrate that after 24 weeks a significantly larger number of SSc patients responded favourably to MTX compared to placebo treatment. Moreover, of all patients who received MTX for at least 24 weeks and completed the trial, 68% responded favourably to MTX therapy with reductions in skin thickness or improvements in general well-being and without further damage to internal organs after 48 weeks. Owing to the small number of patients involved in this study and the limited period of follow-up, long-term prospective trials examining efficacy and toxicity and randomized trials comparing MTX with, for example, D-penicillamine or cyclosporin, will determine the position of MTX therapy in the treatment of scleroderma. 
